Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 16/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 16/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SCNN1A | P37088 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628471 | 0.91 | SCN5A (0.84) | SCN5ASCN2ANPC1CYP1A2CYP2C9 | |
| SCHEMBL4629281 | 0.83 | SCN2A (0.71) | SCN5ASCN2ANPC1CYP1A2CYP2C9 | |
| SCHEMBL4629470 | 0.82 | SCN5A (0.83) | SCN5ASCN2ASCNN1A | |
| SCHEMBL4628434 | 0.81 | SCN5A (0.68) | SCN5ASCN2ANPC1CYP1A2CYP2C9 | |
| SCHEMBL4628444 | 0.80 | SCN5A (0.70) | SCN5ASCN2ANPC1 | |
| SCHEMBL4628745 | 0.79 | SCN5A (0.65) | SCN5ASCN2ANPC1 | |
| SCHEMBL4628962 | 0.77 | SCN5A (1.00) | SCN5ASCN2ASCNN1A | |
| SCHEMBL4629432 | 0.77 | SCN2A (1.00) | SCN5ASCN2A | |
| SCHEMBL4628688 | 0.77 | SCN5A (1.00) | SCN5ASCN2ASCNN1A | |
| SCHEMBL4627593 | 0.76 | SCN2A (1.00) | SCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN5A 1196/4885SCN2A 1613/4885NPC1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.